Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for behavior disorders in learning disabled children
NCT00254930Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Sep 2003
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of risperidone in child behavior disorders, sponsored by Janssen-Cilag. Primary endpoint: Aberrant Behaviour Checklist Total Score at 6 months. Started Sep 2003; status: completed.
02
Drugs
risperidone
03
Conditions
child behavior disorders
Beyond the preview
Go deeper on NCT00254930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254930.